Top cited articles
Acceptance rate:
14%
Time to first decision with review:
33 days*
Acceptance to publication:
20 days*
Impact Factor (JCR):
20.3
Impact Factor rank (JCR):
2/57
Citescore:
35
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
2023 ACR/EULAR antiphospholipid syndrome classification criteria
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance